PHASE Scientific, a biotechnology company revolutionizing early disease detection through proprietary urine-based diagnostics, announced the completion of a $34 million Series A funding round. This funding round was led by Value Partners Group with significant backing from new healthcare-focused investors and continued support from existing global backers.
This deal represents the largest Series A raise in Asia’s diagnostic technology sector since 2019, reflecting robust investor conviction in PHASE Scientific’s innovative PHASIFY technology and ambitious growth strategy.
Building on patented PHASIFY urine concentration technology, which captures over ten times more biomarkers than current industry gold standards. And PHASE Scientific is the only player advancing a urine-based liquid biopsy diagnostics pipeline.
The company is also developing a comprehensive suite of non-invasive tests for early detection of cancers, women’s health conditions, and infectious diseases.
Unlike traditional invasive screening methods, PHASIFY enables convenient, at-home sample collection, enabling proactive health management and preventive care.
PHASE Scientific has shown strong market traction with the launch and commercialization of over 30 innovative diagnostic products across multiple health categories, including respiratory, gastrointestinal, women’s, sexual, pediatric health, and oncology. So far, the company has distributed more than 100 million tests in over 30 countries and conducted over 8 million laboratory tests worldwide. Created on this commercial success, PHASE Scientific has developed the world’s first urine-based HPV test—a major breakthrough that has achieved significant clinical validation and global recognition.
Launched in 2015, the company is based in Hong Kong SAR with a cross-border setup in Southern California, U.S.A., and China’s Greater Bay Area, which allows it to leverage the strengths of each region for research, development, and commercialization, positioning PHASE Scientific at the nexus for healthcare innovation on a global stage.
KEY QUOTES:
“The successful close of this landmark Series A financing validates the transformative potential of our technology and the growing global demand for accessible, accurate early disease detection. With this capital, we will accelerate R&D and commercialization efforts to bring a comprehensive suite of next-generation urine-based diagnostics to market. Our mission is to empower millions worldwide with non-invasive, user-friendly testing that can save lives through earlier intervention.”
Dr. Ricky Chiu, Founder, Chairman and CEO of PHASE Scientific
“We are delighted to become a partner of PHASE Scientific as it rapidly grows and addresses critical unmet needs in early disease detection. Its innovative technology represents a paradigm shift, offering an unparalleled combination of clinical precision and patient-centric solutions that accelerates the development of early disease detection. This aligns with our strategy to back category-defining leader with strong management, clear strategic differentiation, and best-in-class healthcare technologies that deliver both societal impact and scalable commercial potential.”
Dr. Chuen Yan Leung, Partner (Healthcare Investments) of Value Partners Group
